The Open Payments Expansion Act requires pharmaceutical and medical device manufacturers to publicly disclose all payments they make to patient advocacy organizations, similar to existing disclosure rules for payments to doctors and hospitals. Starting March 31, 2027, and every 90 days thereafter, manufacturers must report to the federal government the name of each patient advocacy organization and the amount of money provided, including both direct payments and indirect payments made through third parties. The bill defines patient advocacy organizations as nonprofits that provide education and support services related to specific medical conditions or assist vulnerable individuals and families dealing with health issues. This transparency requirement aims to help the public understand potential financial relationships between drug and device makers and organizations that advocate for patients, though the legislation includes no specific funding allocation beyond administration costs.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.